Alembic Pharma Q2 net surges 81% to ₹335 crore
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
· 11/5/2026, 11:20:12 AM· 2 min read
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
Read original story →
